Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. J Natl Cancer Inst. 2023 11 08; 115(11):1404-1419.
-
Inoue Y, Inui N, Karayama M, Asada K, Fujii M, Matsuura S, Uto T, Hashimoto D, Matsui T, Ikeda M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Suda T. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy. Cancer Immunol Immunother. 2023 Aug; 72(8):2717-2728.
-
Obrochta CA, Parada H, Murphy JD, Nara A, Trinidad D, Araneta MRH, Thompson CA. The impact of patient travel time on disparities in treatment for early stage lung cancer in California. PLoS One. 2022; 17(10):e0272076.
-
Messeha SS, Nezami MA, Hager S, Soliman KFA. A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition. Anticancer Res. 2022 Jan; 42(1):441-447.
-
Qui?ones-Avila V, Ortiz-Ortiz KJ, R?os-Motta R, Mar?n-Centeno H, Tortolero-Luna G. Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer in Puerto Rico. BMC Palliat Care. 2021 Aug 13; 20(1):127.
-
Huo J, Hong YR, Turner K, Diaby V, Chen C, Bian J, Grewal R, Wilkie DJ. Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2020 12; 16(12):e1532-e1542.
-
Darling HS, Viswanath S, Singh R, Ranjan S, Pathi N, Rathore A, Pathak A, Sud R. A clinico-epidemiological, pathological, and molecular study of lung cancer in Northwestern India. J Cancer Res Ther. 2020 Jul-Sep; 16(4):771-779.
-
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung?Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clin Lung Cancer. 2020 11; 21(6):520-526.
-
Urushiyama H, Jo T, Yasunaga H, Michihata N, Matsui H, Hasegawa W, Takeshima H, Sakamoto Y, Hiraishi Y, Mitani A, Fushimi K, Nagase T, Yamauchi Y. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses. Cancer Med. 2018 10; 7(10):4863-4869.
-
Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98.